Burger King is debuting an entire line of Royal Crispy Chicken Sandwiches this month to replace its Ch'King Sandwiches.
The BK Royal Crispy Chicken Sandwiches come in four varieties: Classic, Spicy, Bacon & Swiss Cheese and Southern BBQ.
A crispy white flesh breast fillet, savory sauce, lettuce, and tomatoes are all included in the standard Royal Crispy Chicken Sandwich, which is served on a toasted potato bun.
The other option is the hot version, which has the same fixings but with a triple pepper spicy glaze over the chicken fillet.
The Southern BBQ Royal has spiced BBQ sauce, bacon, caramelized onions, and melty cheese, while the Bacon and Swiss Cheese Royal Crispy Chicken Sandwich has a chicken fillet covered with savory sauce, creamy Swiss cheese, bacon, lettuce, and tomatoes.
Burger King hasn't publicly acknowledged this significant change yet, and its not known how or if the chicken is any different on the new sandwiches.
Burger King began testing the sandwiches in select markets in May.
The sandwiches will be available nationwide.


Iraq Seeks 6 Million Bpd OPEC+ Oil Quota
The Beauty Beneath the Expressway: A Journey from Self to Service
Google promotes ‘teacher approved’ apps for kids. Here’s what parents should know
Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation
Can your cat recognise you by scent? New study shows it’s likely
OpenAI Targets Specialized Industries as Enterprise AI Demand Grows
6 simple questions to tell if a ‘finfluencer’ is more flash than cash
Kioxia Rules Out SK Hynix Manufacturing Partnership
Asian Currencies Steady as Yen Holds Firm, Oil Tops $100
Gold Prices Steady as Hot PPI Boosts Fed Rate Hike Bets
Why have so few atrocities ever been recognised as genocide?
BOJ Set to Raise Rates to 1.25% as Inflation Risks Build
Volkswagen Job Cuts Put Lower Saxony Leader Under Political Pressure
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities
AI is driving down the price of knowledge – universities have to rethink what they offer
Global Central Banks Brace for More Rate Hikes as Inflation Risks Rise
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 



